New Aids fighting drug

German scientists have discovered a substance known as a peptide that thwarts the Aids virus and causes far fewer side-effects than existing anti-HIV drugs, they said.

The breakthrough was reported in the science journal Science Translational Medicine after it had been tested on 18 Aids patients.

But the scientists at Hanover university hospital or MHH in northern Germany said they have yet to find a way to put the substance, VIR-576, in a pill. All the test patients received it as an intravenous drip.

Variants of the new therapy could also be devised to fight measles, hepatitis C and Ebola disease.

VIR-576 is a protein that smothers human immunodeficiency virus, stopping it docking with cells in the human body.

New therapy that reduces side effects

"It is a completely new therapy approach which we hope will reduce side effects," said Reinhold E Schmidt of MHH. Other existing medicines offered since the mid-1990s work by proofing cells of the body against the virus.

"Our peptide works on the virus, not on the cells, so some of the side-effects won't happen at all," he said.

Current anti-Aids medications ensure an almost normal life span for HIV-infected people but raise the risk of strokes and liver damage. VIR-576 caused some diarrhoea, but no other major side effects, the tests suggested.

Schmidt cautioned that it could take years before VIR-576 was available from pharmacies as a medicine.

(Sapa, December 2010)

Read more:

HIV/Aids and nutrition

No gender based difference seen in anti-HIV drug response

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For only R75 per month, you have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today.
Subscribe to News24
Voting Booth
Have you entered our Health of the Nation survey?
Please select an option Oops! Something went wrong, please try again later.
Results
Yes
29% - 9743 votes
No
71% - 23840 votes
Vote